TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Teles AG Informationstechnologien ( (DE:TLIK) ) just unveiled an update.
Arzneiwerk AG VIDA announced that it is no longer required to prepare consolidated financial statements for 2024 due to changes in its investment in EuroRX Arzneimittel GmbH. This change will result in cost savings for the preparation of annual financial statements, while the key figures of EuroRX Arzneimittel GmbH will continue to be published.
More about Teles AG Informationstechnologien
Arzneiwerk AG VIDA is a specialized pharmaceutical supplier that ensures optimal pharmaceutical care for patients with a digitalized supply chain. The company delivers medicines for cancer, autoimmune deficiencies, and combination therapies for personalized medicine quickly and reliably throughout Europe. It benefits from the growing need for indication-specific drugs across Europe and is one of the largest specialty pharmacy companies in Germany, supplying predominantly German medicines with a high export share.
YTD Price Performance: -18.55%
Average Trading Volume: 52
Technical Sentiment Signal: Buy
Current Market Cap: €3.99M
For an in-depth examination of TLIK stock, go to TipRanks’ Stock Analysis page.